Item 7.01. Regulation FD Disclosure.

On April 8, 2022, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company has paused enrollment in clinical trials with BCX9930 while it investigates elevated serum creatinine levels seen in some patients. Following this announcement, the Company has received many inquiries from investors confused by independent commentary from some analysts and media outlets which reflect their own, independent opinions but do not represent the Company's views or the facts provided by the Company.

While Company officers and other members of management have responded to many inquiries from analysts and investors since the announcement, to further address this confusion and provide clarity, the Company wishes to reiterate the following:

· The Company has paused enrollment of new patients in clinical trials with


   BCX9930; however, patients currently enrolled in the trials continue to receive
   BCX9930 at this time. Patients currently enrolled are primarily PNH patients.

· Until the Company completes its recently initiated investigation and consults


   its medical experts and appropriate regulatory authorities, the Company cannot
   predict the likelihood of any potential outcomes, including, but not limited
   to, the potential resumption of trial enrollments, or a potential decision not
   to continue the trials. The Company is working to complete the investigation as
   quickly as possible.

· As the Company has explained in response to investor inquiries, because the


   situation is fluid and information can change quickly, the Company is focused
   on completing the investigation in order to have the full picture of the
   situation before providing additional details surrounding the pause in trial
   enrollments.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements, including statements regarding BioCryst's plans for its BCX9930 program. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the timing and results of the investigation described in this Current Report on Form 8-K regarding BCX9930; ongoing and future preclinical and clinical development of BCX9930 may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; and the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on product candidates, or may impose a clinical hold with respect to product candidates. Please refer to the all documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's forward-looking statements.

© Edgar Online, source Glimpses